Cargando…

Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver

OBJECTIVE: Therapy for hepatocellular carcinoma (HCC) is a major challenge, and targeted therapies provide only a modest benefit in terms of overall survival. Treatment with antibodies to programmed cell death protein 1 (PD-1)/PD-L1 can restore the functions of tumor-infiltrating T cells in HCC and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Xiangdong, Wang, Xueqing, Yu, Wenhui, Yang, Qing, Li, Yan, Jin, Yanxia, Su, Yanting, Song, Jiaqi, Xu, Bo, Sun, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8610148/ https://www.ncbi.nlm.nih.gov/pubmed/33710817 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0278

Ejemplares similares

AAGL practice report: practice guidelines on intrauterine adhesions developed in collaboration with the European Society of Gynaecological Endoscopy (ESGE)
Publicado: (2017)

3’-Sulfo-TF Antigen Determined by GAL3ST2/ST3GAL1 Is Essential for Antitumor Activity of Fungal Galectin AAL/AAGL
por: Li, Yang, et al.
Publicado: (2021)

Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma
por: Wang, Jialiang, et al.
Publicado: (2023)

Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
por: Zhao, Bonan, et al.
Publicado: (2021)

Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
por: Dharmapuri, Sirish, et al.
Publicado: (2020)

Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy
por: Zhu, Zhen-Feng, et al.
Publicado: (2022)

Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer
por: Quan, Yibo, et al.
Publicado: (2023)

Synergistic anti-liver cancer effects of curcumin and total ginsenosides
por: Deng, Zhe, et al.
Publicado: (2020)

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma
por: Cheng, Yang, et al.
Publicado: (2017)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Synergistic effect of IFN-γ and IL-1β on PD-L1 expression in hepatocellular carcinoma
por: Numata, Yasunao, et al.
Publicado: (2022)

Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis
por: Borchers, Andrea T., et al.
Publicado: (2009)

Expression and Prognostic Value of Tumor-Infiltrating Lymphocytes and PD-L1 in Hepatocellular Carcinoma
por: Nie, Hanxiao, et al.
Publicado: (2021)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

Progress of PD-1/PD-L1 signaling in immune response to liver transplantation for hepatocellular carcinoma
por: Ju, Feng, et al.
Publicado: (2023)

SYNERGISTIC INTERACTION OF MACROPHAGES AND LYMPHOCYTES IN ANTIGEN-INDUCED TRANSFORMATION OF LYMPHOCYTES
por: Seeger, Robert C., et al.
Publicado: (1970)

The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
por: Yu, Cheng-Chan, et al.
Publicado: (2020)

Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy
por: Shin, Jae Hun, et al.
Publicado: (2016)

The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer
por: Sheng, Zhixin, et al.
Publicado: (2017)

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
por: Pan, Yu, et al.
Publicado: (2019)

The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer
por: Kang, Bo, et al.
Publicado: (2022)

Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma
por: Choi, John, et al.
Publicado: (2021)

WSX1 act as a tumor suppressor in hepatocellular carcinoma by downregulating neoplastic PD-L1 expression
por: Wu, Man, et al.
Publicado: (2021)

Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma
por: Yoo, Jeong-Ju, et al.
Publicado: (2019)

Monocarboxylate transporter upregulation in induced regulatory T cells promotes resistance to anti-PD-1 therapy in hepatocellular carcinoma patients
por: Zhou, Jinren, et al.
Publicado: (2022)

Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
por: Chen, Jiming, et al.
Publicado: (2022)

Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer
por: Meng, Jinyu, et al.
Publicado: (2021)

Screening and identification of an anti-PD-1 nanobody with antitumor activity
por: Zhang, Yanting, et al.
Publicado: (2023)

Effects of anti‐human T lymphocyte immune globulins in patients: new or old
por: Wang, Diane C., et al.
Publicado: (2016)

Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma
por: Feng, Duan, et al.
Publicado: (2017)

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
por: Lim, Mir, et al.
Publicado: (2023)

The correlation between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with nonalcoholic fatty liver disease: a cross-sectional study
por: Zhou, Yuge, et al.
Publicado: (2022)

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
por: Alden, Stephanie L., et al.
Publicado: (2023)

Oxaliplatin-Resistant Hepatocellular Carcinoma Drives Immune Evasion Through PD-L1 Up-Regulation and PMN-Singular Recruitment
por: Zhang, Feng, et al.
Publicado: (2022)

Synergistic anti-tumor efficacy by combination therapy of a self-assembled nanogel vaccine with an immune checkpoint anti-PD-1 antibody
por: Miura, Risako, et al.
Publicado: (2020)

A Tumor-Immune Interaction Model for Synergistic Combinations of Anti PD-L1 and Ionizing Irradiation Treatment
por: Byun, Jong Hyuk, et al.
Publicado: (2020)

Synergistic effect of the anti-PD-1 antibody with blood stable and reduction sensitive curcumin micelles on colon cancer
por: Gong, Feirong, et al.
Publicado: (2021)

Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer
por: Cheng, Bo, et al.
Publicado: (2022)

Active recruitment of anti–PD-1–conjugated platelets through tumor-selective thrombosis for enhanced anticancer immunotherapy
por: Wang, Yixin, et al.
Publicado: (2023)

PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
por: Sideras, Kostandinos, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8dr7pd5n3s11edg7u3o7fhdp58